This post was originally published on this site A $102.2 million Pelotonia donation will help establish an institute at Ohio State University (OSU) that will focus exclusively on groundbreaking immuno-oncology therapies and cures for cancer. Disbursed over five years, the funds will support research to be conducted by the Pelotonia Institute for Immuno-Oncology (PIIO) at the…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
USPSTF Updates Recommendations on Testing for BRCA-related Cancers in Women
This post was originally published on this site The United States Preventive Services Task Force (USPSTF) has revised their recommendations on testing for cancer-associated BRCA1/2 mutations in women, suggesting risk assessment only in those with a personal or family history of cancers associated with these mutations. These guidelines were published in the journal JAMA in a…
Cirmtuzumab-Imbruvica Combo Trial Enrolling CLL, SLL Patients for Phase 2
This post was originally published on this site Following promising early efficacy results for a cirmtuzumab–Imbruvica treatment combo, a Phase 2 clinical trial has now been opened to people with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The opening of this randomized trial was based on the promising results seen in the prior Phase 1 stage, in…
EU Committee Recommends Orphan Drug Status for Ziopharm’s IL-12 Gene Therapy for Glioblastoma
This post was originally published on this site A European Medicines Agency (EMA) committee has recommended orphan drug designation for Ziopharm Oncology‘s interleukin (IL)-12 gene therapy — known as the Controlled IL-12 platform — for the treatment of glioblastoma, a very aggressive type of brain cancer. The European Commission will now decide whether or not to grant…
10 Commandments for Surviving Breast Cancer
This post was originally published on this site I hate giving advice, but I’ve learned lessons through my breast cancer journey that may be helpful to others in similar situations. After my diagnosis, a doctor told me I had three months to live. Against the odds, I survived, and along the way, I experienced profound…
Request for Xtandi to Treat Metastatic Hormone-sensitive Prostate Cancer Before FDA
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has agreed to review Astellas Pharma and Pfizer‘s application for Xtandi (enzalutamide), requesting its approved use be expanded to include men whose metastatic prostate cancer still responds to hormone therapy. The supplemental new drug application, covering men with metastatic hormone-sensitive prostate…
Rubraca Conditionally Rejected for Use on NHS England for Recurrent Ovarian Cancer
This post was originally published on this site Rubraca (rucaparib), a therapy for relapsed or progressive ovarian, fallopian, or primary peritoneal cancer, was provisionally rejected for use on England’s National Health Service (NHS). In justifying its decision, the National Institute of Health and Care Excellence (NICE), the U.K. agency that provides healthcare guidance, cited a…
Darzalex OK’d to Treat Multiple Myeloma Patients in Japan Not Eligible for Stem Cell Transplant
This post was originally published on this site People in Japan newly diagnosed with multiple myeloma and ineligible for a stem cell transplant can now use a combination of Darzalex (daratumumab) and standard treatment, the companies behind the therapy announced. The approval, by the country’s Ministry of Health, Labor and Welfare, was based on data from the ALCYONE Phase…
Adalimumab May Safely Treat Sarcoidosis in Hepatitis C, Case Report Suggests
This post was originally published on this site People with hepatitis C who develop sarcoidosis may be safely treated with adalimumab, marketed by Abbvie as Humira, a case report suggests. The case was described in a study, “Sarcoidosis with concomitant hepatitis C infection treated successfully with adalimumab,” which was published in the Journal of the German Society…
Grant to Fund CAR T-cell Trial for HER2-Positive BC with Brain Metastases
This post was originally published on this site The California Institute for Regenerative Medicine (CIRM) has granted a $9.28 million award to a group of City of Hope researchers carrying out a first-in-human Phase 1 clinical trial testing the safety and efficacy of CAR T-cell therapy for the treatment of women with HER2-positive breast cancer…
Lynparza-Avastin Combo Cuts Risk of Disease Progression, Death in Advanced OC, Phase 3 Trial Shows
This post was originally published on this site When added to Avastin (bevacizumab), Lynparza (olaparib) reduces the risk of disease progression and death in women with advanced forms of ovarian cancer who are responding to their first-line treatment with platinum-based chemotherapy, a Phase 3 trial shows. Lynparza is an oral anti-cancer treatment jointly developed by AstraZeneca and Merck…
Kalytera’s Cannabidiol Prevents Graft-Versus-Host-Disease After Bone Marrow Transplant, Data Show
This post was originally published on this site Kalytera’s cannabidiol (CBD) compound efficiently prevents graft-versus-host disease (GVHD) in patients receiving bone marrow transplants from matched unrelated donors, interim data from a Phase 2 study show. Considering the study’s positive results so far, the company announced that it will halt the Phase 2 study and proceed directly…